ExodusPoint Capital Management LP grew its stake in shares of Atreca, Inc. (NASDAQ:BCEL – Free Report) by 356.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 509,886 shares of the company’s stock after acquiring an additional 398,116 shares during the period. ExodusPoint Capital Management LP owned 1.30% of Atreca worth $581,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of BCEL. Advisor Group Holdings Inc. grew its holdings in shares of Atreca by 111.8% during the 1st quarter. Advisor Group Holdings Inc. now owns 16,573 shares of the company’s stock valued at $52,000 after acquiring an additional 8,750 shares in the last quarter. Raymond James & Associates acquired a new stake in shares of Atreca during the 1st quarter valued at about $199,000. BlackRock Inc. lifted its holdings in shares of Atreca by 0.4% during the 1st quarter. BlackRock Inc. now owns 2,963,843 shares of the company’s stock valued at $9,395,000 after buying an additional 12,556 shares during the last quarter. State Street Corp raised its holdings in shares of Atreca by 16.3% during the 1st quarter. State Street Corp now owns 555,247 shares of the company’s stock valued at $1,760,000 after purchasing an additional 77,798 shares in the last quarter. Finally, IHT Wealth Management LLC bought a new position in shares of Atreca during the 1st quarter valued at $41,000. 34.91% of the stock is currently owned by hedge funds and other institutional investors.
Atreca Price Performance
BCEL opened at $0.36 on Thursday. The firm has a market capitalization of $13.97 million, a P/E ratio of -0.16 and a beta of 1.17. The stock’s 50 day moving average price is $0.75 and its two-hundred day moving average price is $1.01. Atreca, Inc. has a 12-month low of $0.33 and a 12-month high of $2.22.
Analyst Ratings Changes
BCEL has been the topic of a number of analyst reports. Stifel Nicolaus lowered Atreca from a “buy” rating to a “hold” rating in a report on Friday, August 11th. HC Wainwright lowered Atreca from a “buy” rating to a “neutral” rating in a report on Friday, August 11th. Brookline Capital Management lowered shares of Atreca from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Finally, Wedbush lowered shares of Atreca from an “outperform” rating to a “neutral” rating in a research report on Monday, August 14th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $10.75.
Read Our Latest Research Report on Atreca
About Atreca
Atreca, Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Read More
- Five stocks we like better than Atreca
- The 3 Best Fintech Stocks to Buy Now
- These Quality Dividend Kings Grow their Dividends the Fastest
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Growth Stocks to Buy in September
- Investing in Agriculture 101: How to Invest in Agriculture
- 3 Underappreciated Stocks with Nowhere to Go But Up
Want to see what other hedge funds are holding BCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atreca, Inc. (NASDAQ:BCEL – Free Report).
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.
